Lupins Pharma Dynamics signs distribution agreement with Creso Pharma
Category: #health  By Pankaj Singh  Date: 2019-08-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Lupins Pharma Dynamics signs distribution agreement with Creso Pharma
  • The deal gives Lupin access to Creso’s cannaQIX product range, which are nutraceuticals based on cannabidiol hemp oil, utilized for reducing stress and help with nervous and mental functions.
     
  • Creso granted Pharma Dynamics sole distribution power of its products all over the African continent.

Lupin, an international pharmaceutical company, reportedly announced that its South African subsidiary, Pharma Dynamics, has inked a commercial pact with Creso Pharma, a pharmaceutical company that focuses on cannabis related-products, for cannaQIX products based on hemp oil.

Lupin stated that according to the agreement, Creso granted Pharma Dynamics sole distribution power of its products throughout Uganda, Mozambique, Angola, Lesotho, Swaziland, Zimbabwe, Botswana, Namibia and South Africa.

Erik Roos, CEO at Pharma Dynamics, stated that company expects this agreement to be the base for a long-lasting relationship as the company grows its business into scheduled markets along with nutraceuticals.

Roos added that Creso Pharma is well-known across the world for its cannabis products with several product distribution deals already in place across various countries of Asia-Pacific and Europe.

Creso Pharma co-founder and CEO, Miri Halperin Wernli, stated that Creso is encouraged to witness a broader array of opportunities opening to get premium hemp oil based nutraceutical products for consumers in South Africa.

The cannaQIX product range, which are nutraceuticals based on cannabidiol hemp oil, are utilized for reducing stress and help with nervous and mental functions.

According to reports, any financial details pertaining to the commercial agreement have not been unveiled by two involved parties yet.

About Lupin Limited:

Lupin Pharmaceuticals is one of the leading pharmaceutical companies of India. Lupin Pharmaceuticals is aimed at offering high-quality, generic and branded medications trusted by patients and healthcare professionals across the world. Lupin Limited based in Mumbai is entirely focused at research.

About Creso Pharma:

Creso Pharma was founded in 2015 and is pharmaceutical company based In Australia. Creso implements pharmaceutical expertise to market, produce and develop a range of products based on cannabis to better human and animal lives.

 

 

Source Credit: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupins-south-african-arm-inks-commercial-pact-with-creso-pharma/articleshow/70842617.cms



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...